Aurinia Pharmaceuticals Inc. (AUPH) — Financial statements
Income statement, balance sheet, and cash flow for Aurinia Pharmaceuticals Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 283↑20.4% | 235↑34.0% | 176↑31.0% | 134↑193.9% | 46 | |
| Cost of Revenue | 33↑15.6% | 28↑99.7% | 14↑149.8% | 6↑419.2% | 1 | |
| Gross Profit | 250↑21.0% | 207↑28.2% | 161↑25.7% | 128↑188.4% | 45 | |
| Operating Expenses | ||||||
| R&D Expenses | 33↑56.4% | 21↓58.1% | 50↑10.3% | 45↓12.0% | 51 | |
| General & Administrative Expenses | 0.00↓100.0% | 158↓19.0% | 195↓0.7% | 196↑14.5% | 171 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 14 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 102↓40.8% | 172↓11.8% | 195↓0.7% | 196↑14.5% | 171 | |
| Other Expenses | 11↓40.4% | 19↑123.9% | 8↑650.2% | -2↓157.0% | 3 | |
| Operating Expenses | 145↓31.2% | 212↓16.4% | 253↑5.5% | 240↑6.5% | 225 | |
| Total Costs & Expenses | 178↓25.7% | 240↓10.2% | 267↑8.8% | 246↑8.5% | 226 | |
| Operating Results | ||||||
| Operating Income | 105↑2338.4% | -5↑94.9% | -92↑17.7% | -111↑38.3% | -181 | |
| Depreciation & Amortization | 9↓52.3% | 19↑67.0% | 12↑330.4% | 3↓2.0% | 3 | |
| EBITDA | 128↑302.7% | 32↑150.3% | -63↑39.2% | -104↑41.6% | -177 | |
| EBIT | 118↑864.6% | 12↑116.4% | -75↑29.8% | -106↑41.0% | -180 | |
| Interest & Other Income | ||||||
| Net Interest Income | 9↓23.8% | 12↓14.7% | 14↑177.9% | 5↑867.5% | 0.53 | |
| Interest Income | 14↓20.0% | 17↓0.2% | 17↑232.1% | 5↑867.5% | 0.53 | |
| Interest Expense | 4↓10.4% | 5↑74.2% | 3 | 0.00 | 0.00 | |
| Non-Operating Income | -14↑20.0% | -17↑0.2% | -17↓232.1% | -5↓867.5% | -0.53 | |
| Other Income / Expenses | 9↓23.8% | 12↓14.7% | 14↑177.9% | 5↑867.5% | 0.53 | |
| Income Before Tax | 114↑1432.7% | 7↑109.6% | -77↑27.2% | -106↑41.0% | -180 | |
| Income Tax Expense | -173↓10303.1% | 2↑207.8% | 0.55↓69.9% | 2↑140.5% | 0.76 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 287↑4893.1% | 6↑107.4% | -78↑27.9% | -108↑40.2% | -181 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 287↑4893.1% | 6↑107.4% | -78↑27.9% | -108↑40.2% | -181 | |
| Bottom-Line Net Income | 287↑4893.1% | 6↑107.4% | -78↑27.9% | -108↑40.2% | -181 | |
| EPS (Basic) | 2.14↑5250.0% | 0.04↑107.4% | -0.54↑28.9% | -0.76↑45.7% | -1.40 | |
| EPS (Diluted) | 2.07↑5167.2% | 0.04↑107.3% | -0.54↑28.9% | -0.76↑45.7% | -1.40 | |
| Weighted Average Shares | 134↓6.1% | 143↓0.1% | 143↑0.9% | 142↑9.7% | 129 | |
| Weighted Average Diluted Shares | 139↓5.1% | 146↑2.1% | 143↑0.9% | 142↑9.7% | 129 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.